At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 98 enrolled
Drug / intervention
ZPL-3893787 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Determine the Effects of 8 Weeks Treatment With Oral ZPL-3893787 (30 mg od x 56 Days) on Pruritus in Adult Subjects With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating ZPL-3893787 and Placebo for Atopic Dermatitis. Completed, enrolled 98 participants across 17 sites in 4 countries.
Detailed Summary
This was a randomized, double blind, placebo controlled, parallel group study in approximately 90 subjects with moderate-severe AD Eczema Area and Severity Index (EASI) ≥12 and ≤ 48 (0-72 scale). Following a run-in subjects were randomized to receive either oral 30 mg ZPL-3893787 once daily (od) or placebo od for 8 weeks (56 days).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesBelgium, Germany, Poland, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartMay 2015
Primary CompletionJan 2016
Study CompletionFeb 2016
TodayJul 2026
First PostedApr 23, 2015
Enrollment StartMay 18, 2015
Primary CompletionJan 1, 2016
Study CompletionFeb 3, 2016
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 11.2 years ago
Interventions
ZPL-3893787drug
ZPL-3893787
Placebodrug
Matched Placebo